Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Goto 0, 1, Next
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2023-02-09
4:19 pm
Sale
13GCentury Therapeutics, Inc.
IPSC
Versant Venture Capital VI L.P.11,452,014
19.4%
-914,800decrease
(-7.40%)
View
2023-01-13
4:09 pm
Sale
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.0
0%
-2,236,888decrease
(Position Closed)
View
2022-05-09
5:26 pm
Purchase
13DTempest Therapeutics, Inc.
TPST
Versant Venture Capital VI L.P.2,118,644
20.5%
940,173increase
(+79.78%)
View
2022-02-10
8:39 pm
Purchase
13GCentury Therapeutics, Inc.
IPSC
Versant Venture Capital VI L.P.12,366,814
22.6%
12,366,814increase
(New Position)
View
2022-02-10
7:41 pm
Purchase
13GTempest Therapeutics, Inc.
TPST
Versant Venture Capital VI L.P.1,178,471
17.1%
1,178,471increase
(New Position)
View
2022-01-13
4:34 pm
Unchanged
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.2,236,888
8.5%
0
(Unchanged)
View
2021-10-27
4:32 pm
Unchanged
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.2,236,888
8.6%
0
(Unchanged)
View
2021-07-09
4:43 pm
Purchase
13DGraphite Bio, Inc.
GRPH
Versant Venture Capital VI L.P.14,708,398
26.3%
14,708,398increase
(New Position)
View
2021-07-08
4:31 pm
Purchase
13DMonte Rosa Therapeutics, Inc.
GLUE
Versant Venture Capital VI L.P.6,799,115
15.3%
6,799,115increase
(New Position)
View
2021-06-21
4:44 pm
Sale
13DAligos Therapeutics, Inc.
ALGS
Versant Venture Capital VI L.P.1,457,937
3.8%
-485,979decrease
(-25.00%)
View
2021-05-24
4:27 pm
Unchanged
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.2,236,888
8.6%
0
(Unchanged)
View
2021-05-03
4:57 pm
Sale
13DAligos Therapeutics, Inc.
ALGS
Versant Venture Capital VI L.P.1,943,916
5.1%
-485,979decrease
(-20.00%)
View
2021-04-08
4:31 pm
Purchase
13DLAVA Therapeutics N.V.
LVTX
Versant Venture Capital VI L.P.3,407,157
13.4%
3,407,157increase
(New Position)
View
2021-04-05
4:33 pm
Unchanged
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.2,236,888
8.6%
0
(Unchanged)
View
2021-03-01
5:16 pm
Sale
13DOyster Point Pharma, Inc.
OYST
Versant Venture Capital VI L.P.2,236,888
8.6%
-325,000decrease
(-12.69%)
View
2021-02-12
8:41 pm
Sale
13GAkero Therapeutics, Inc.
AKRO
Versant Venture Capital VI L.P.777,727
2.2%
-2,878,858decrease
(-78.73%)
View
2020-12-03
4:47 pm
Sale
13DBlack Diamond Therapeutics, Inc.
BDTX
Versant Venture Capital VI L.P.4,328,883
12%
-1,031,634decrease
(-19.25%)
View
2020-11-20
5:32 pm
Sale
13DBlack Diamond Therapeutics, Inc.
BDTX
Versant Venture Capital VI L.P.5,360,517
14.9%
-980,734decrease
(-15.47%)
View
2020-10-30
4:25 pm
Purchase
13DAligos Therapeutics, Inc.
ALGS
Versant Venture Capital VI L.P.2,429,895
7.2%
2,429,895increase
(New Position)
View
2020-09-25
4:37 pm
Sale
13DBlack Diamond Therapeutics, Inc.
BDTX
Versant Venture Capital VI L.P.6,341,251
17.7%
-457,424decrease
(-6.73%)
View
Goto 0, 1, Next